[{"orgOrder":0,"company":"Berlin Chemie","sponsor":"Helsinn Advanced Synthesis","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Fosnetupitant Chloride","moa":"||Neurokinin 1 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Berlin Chemie","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Berlin Chemie \/ Helsinn Advanced Synthesis","highestDevelopmentStatusID":"15","companyTruncated":"Berlin Chemie \/ Helsinn Advanced Synthesis"},{"orgOrder":0,"company":"Berlin Chemie","sponsor":"Carrick Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Samuraciclib","moa":"Cyclin-dependent kinase 7 (CDK7)","graph1":"Oncology","graph2":"Phase II","graph3":"Berlin Chemie","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Berlin Chemie \/ Berlin Chemie","highestDevelopmentStatusID":"8","companyTruncated":"Berlin Chemie \/ Berlin Chemie"},{"orgOrder":0,"company":"Berlin Chemie","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"GERMANY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Levothyroxine Sodium","moa":"Thyroid hormone receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Berlin Chemie","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Berlin Chemie \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Berlin Chemie \/ Inapplicable"},{"orgOrder":0,"company":"Berlin Chemie","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"GERMANY","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Ibuprofen","moa":"Cyclooxygenase","graph1":"Undisclosed","graph2":"Phase I","graph3":"Berlin Chemie","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Berlin Chemie \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Berlin Chemie \/ Undisclosed"},{"orgOrder":0,"company":"Berlin Chemie","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"GERMANY","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Tamsulosin","moa":"Adrenergic receptor alpha-1","graph1":"Undisclosed","graph2":"Phase I","graph3":"Berlin Chemie","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet, Prolonged Release","sponsorNew":"Berlin Chemie \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Berlin Chemie \/ Undisclosed"},{"orgOrder":0,"company":"Berlin Chemie","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"GERMANY","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Tamsulosin","moa":"Adrenergic receptor alpha-1","graph1":"Undisclosed","graph2":"Phase I","graph3":"Berlin Chemie","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Berlin Chemie \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Berlin Chemie \/ Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals by Berlin Chemie

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          IFSCC
                          Not Confirmed
                          IFSCC
                          Not Confirmed

                          Details : Tamsulosin is a Other Small Molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of unspecified medical condition.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          August 28, 2025

                          Lead Product(s) : Tamsulosin

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          IFSCC
                          Not Confirmed
                          IFSCC
                          Not Confirmed

                          Details : Tamsulosin is a Other Small Molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of unspecified medical condition.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          July 29, 2025

                          Lead Product(s) : Tamsulosin

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          IFSCC
                          Not Confirmed
                          IFSCC
                          Not Confirmed

                          Details : Ibuprofen is a Other Small Molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of unspecified medical condition.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          June 25, 2025

                          Lead Product(s) : Ibuprofen

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          IFSCC
                          Not Confirmed
                          IFSCC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          August 09, 2024

                          Lead Product(s) : Levothyroxine Sodium

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          IFSCC
                          Not Confirmed
                          IFSCC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          July 27, 2023

                          Lead Product(s) : Samuraciclib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Recipient : Carrick Therapeutics

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          IFSCC
                          Not Confirmed
                          IFSCC
                          Not Confirmed

                          Details : Berlin-Chemie AG has been granted exclusive rights to import, distribute, promote, market and sell AKYNZEO® and ONICIT® in Russia and CIS region to manage chemotherapy-induced nausea and vomiting.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          January 27, 2020

                          Lead Product(s) : Fosnetupitant Chloride,Palonosetron

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Approved FDF

                          Sponsor : Helsinn Advanced Synthesis

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          07

                          IFSCC
                          Not Confirmed
                          IFSCC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          June 18, 2013

                          Lead Product(s) : Dalteparin sodium

                          Therapeutic Area : Hematology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          IFSCC
                          Not Confirmed
                          IFSCC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          November 25, 2010

                          Lead Product(s) : Nebivolol

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase IV

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank